Cost-effectiveness watchdog NICE has recommended routine NHS use of two new therapies for women with advanced breast cancer – Gilead's Trodelvy and Novartis' Piqray – in England. In a statement, the ...
Chiesi is hoping real world evidence will show its latest COPD triple therapy can help cut hospital admissions for the disease. Trimbow (beclometasone+formoterol+glycopyrronium) combines an inhaled ...
The FDA approved imlunestrant for treatment of certain adults with breast cancer who experience disease progression after at least one prior line of endocrine therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback